At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 51 enrolled
Drug / intervention
AGS-v PLUS Vaccine +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Single-Center, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 5, 2019·Updated Apr 28, 2022
In Brief
A Phase 1 clinical trial evaluating AGS-v PLUS Vaccine, Montanide ISA-51 Adjuvant, and 2 other interventions for Mosquito-Borne Infectious Diseases. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMosquito-Borne Infectious Diseases
CountriesUnited States
CollaboratorsPepTcell Limited
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartJul 2019
Primary CompletionMar 2020
Study CompletionFeb 2021
TodayJul 2026
First PostedJul 5, 2019
Enrollment StartJul 8, 2019
Primary CompletionMar 3, 2020
Study CompletionFeb 23, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.0 years ago
Interventions
AGS-v PLUS Vaccinebiological
Administered by subcutaneous injection
Montanide ISA-51 Adjuvantbiological
Administered by subcutaneous injection
Alhydrogel® Adjuvantbiological
Administered by subcutaneous injection
Saline Placebobiological
Administered by subcutaneous injection